UK approves Novo Nordisk’s semaglutide to prevent cardiovascular events in obese adults
The MHRA's latest approval designates semaglutide as the first weight loss drug to be prescribed for the prevention of cardiovascular events, including cardiovascular death, non-fatal heart attack, and non-fatal stroke